Platform for hit-to-lead identification of antibacterial lysins developed
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
List view / Grid view
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
A compound extracted from the leaf of the American beautyberry re-sensitised methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.
Researchers have created a method to promote the production of new antibiotic or antiparasitic compounds from the genomes of actinobacteria.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Automated detection and isolation of pathogens for multiple samples types.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
Researchers have found that, in rainbow trout models, phages on mucosal surfaces infect pathogenic bacteria, providing protection.